Le Lézard
Classified in: Ebola virus, Health
Subject: CPG

Merck Canada Welcomes the Government of British Columbia's Biosimilars Initiative

KIRKLAND, QC, May 27, 2019 /CNW/ - Today, the Government of British Columbia announced its Biosimilars Initiative, which will transition patients who use specific reference biologic drugs for some rheumatology, dermatology and diabetes indications to a biosimilar. The initiative could help save millions of dollars over the first three years, and could improve access to prescription drugs for patients in the province.i

"I am pleased to see British Columbia lead the way in Canada regarding the use of biosimilars and in recognizing the value these products bring to patients," said Anna Van Acker, President and Managing Director, Merck Canada Inc. "With this announcement, the Government of British Columbia has reinforced the important role biosimilars can play in our healthcare system in helping broaden access not only to biologics, but also to innovative medicines overall. Merck is proud to offer biosimilar products as part of its commitment to delivering patient-centred solutions and believes in the value biosimilars bring to patients and to the sustainability of the healthcare system when savings are reinvested within the system."

The Biosimilars Initiative changes PharmaCare coverage for specific biologic drugs. During the transition period from May 27 - November 25, 2019, PharmaCare will cover both originator and biosimilar versions of the affected drugs to allow patients time to inform themselves and start the transitioning process with their prescriber. Effective November 26, 2019, PharmaCare will only cover the biosimilar versions of the drugs identified for the affected indications.

Merck is committed to assisting eligible patients and their healthcare providers in facilitating transition to its biosimilars through its patient support program.

More information on the announcement can be found at https://news.gov.bc.ca/releases/2019HLTH0080-001072.

Additional information on transitioning, as well as patient resources can be found at www.gov.bc.ca/biosimilars.

For more information about Merck Biosimilars, visit www.merckbiosimilars.ca.

About Merck

For over a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information about our operations in Canada, visit www.merck.ca and connect with us on YouTube and Twitter @MerckCanada.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2018 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

i BC Ministry of Health. B.C. expands use of biosimilars to offer coverage for more treatment options. Available online at:https://news.gov.bc.ca/releases/2019HLTH0080-001072 (Accessed May 2019)


SOURCE Merck Canada Inc.

These press releases may also interest you

at 09:10
Cred International Co., Ltd. has proudly announced that it is introducing the first Japanese Wellness Beauty Center called AN SPA NY in New York. This amazing new spa is located at a luxurious old Castle Hotel & Spa and will offer a wide range of...

at 03:00
World-renowned actor Laurence Fishburne (https://en.wikipedia.org/wiki/Laurence_Fishburne) is the host of the informational program "Behind The Scenes". The show features a wide array of subjects impacting people all around the world today. An...

at 03:00
"Mind, Brain, Body Medicine in Eating Disorders: How One Thing Effects the Next," an examination of the complex interplay between the brain, central nervous system and the body in individuals with eating disorders, will be presented for the first...

22 fév 2020
Sawmill Bay Shellfish Co. Ltd. is recalling certain Sawmill Bay Shellfish brand Pacific Aquacultured Oysters from the marketplace due to norovirus.  Consumers should not consume and distributors, retailers and food service establishments such as...

22 fév 2020
Today, the Association of Black Cardiologists (ABC), Inc., is excited to kick off the official Heart Valve Disease (HVD) Awareness Day activities with a public community educational health event hosted by the Alliance for Aging Research and The...

22 fév 2020
Although many people thrive on praise, not everyone welcomes it. Modesty aside, a study conducted by Queendom.com reveals that some people who dismiss compliments struggle with their sense of self-worth, are more pessimistic, and are less happy....

News published on 27 may 2019 at 19:25 and distributed by: